Clik here to view.
新调研显示，森永的BB536益生菌奶具有胃肠道健康和抗衰老效益
东京 (美国商业资讯) — 日本领先的乳品公司森永乳业株式会社（东京：2264）今天揭晓了一项全国性调研的结果，该调研与日本东京医疗保健大学联合开展，探讨超过20,000 名中年至老年男女的健康状况，旨在调查定期消费含长双歧杆菌BB536 的高钙奶与健康状况之间的关系。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
美国FDA核准武田首个也是唯一的口服蛋白酶体抑制剂NINLARO® (ixazomib)用于治疗多发性骨髓瘤
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，美国食品药品管理局(FDA)已核准首个且唯一的口服蛋白酶体抑制剂NINLARO®...
View ArticleClik here to view.
Solasia and Lee’s Pharma Announce License, Promotion and Supply Agreement...
TOKYO & HONG KONG Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) and Lee’s Pharmaceutical Holdings Limited (hereinafter “Lee’s Pharma”)(SEHK...
View ArticleClik here to view.
ReproCELL Announced: Regarding the Synergistic Effects of Our Complete...
YOKOHAMA, Japan ReproCELL, Inc. (JASDAQ: 4978) announces that at a director meeting held on November 24th, 2015, the complete subsidiary acquisition of English company Biopta Limited (hereafter...
View ArticleClik here to view.
Cell Therapy Catapult Signs Memorandum of Understanding with Kanagawa...
LONDON The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today...
View ArticleClik here to view.
多発性骨髄腫を治療するための経口プロテアソーム阻害薬として初にして唯一の武田薬品のNINLARO®（イキサゾミブ）を米FDAが承認
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Olea Medicalが国際コンテスト「Olea Innovators」を開始
仏ラ・シオタ （ビジネスワイヤ） — 2015年11月30日 MRI／CT画像用の最先端の高度なポストプロセッシング／可視化ソリューションOlea Sphere™を設計したOlea Medical™は、初開催となる「Olea Innovators」コンテストの開始を発表しました。 「Olea...
View ArticleClik here to view.
Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs...
JERUSALEM & OSAKA, Japan Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the two companies have entered into a...
View ArticleClik here to view.
Chugai Pharma Marketing Changed Its Corporate Name to Chugai Pharma Europe
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai located in London, changed its corporate name to Chugai...
View ArticleClik here to view.
Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration with...
TOKYO Sosei Group Corporation (“Sosei”) (TOKYO:4565) today announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer...
View ArticleClik here to view.
Waters Opens Subsidiaries in Malaysia
KUALA LUMPUR, Malaysia Waters Corporation (NYSE: WAT) today announced the opening of a new office in Kuala Lumpur, Malaysia, to more effectively supply all Waters products and services to customers...
View ArticleClik here to view.
Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C...
TOKYO & CAMBRIDGE, Mass. Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the Phase III clinical trial of linaclotide conducted in Japan in...
View ArticleClik here to view.
Medication Adherence Platform, MedAdvisor, Lists on the ASX
MELBOURNE, Australia MedAdvisor Limited (MedAdvisor or Company) an Australian software developer focused on improving health outcomes by placing patients at the centre of connected health platforms,...
View ArticleClik here to view.
The Asian Acne Board and Galderma Join Forces to Improve Understanding and...
LAUSANNE, Switzerland The Asian Acne Board (AAB) and Galderma are inviting candidates to apply for a research grant of 10,000 USD to contribute to the improvement of best practices in the management...
View ArticleClik here to view.
セル・セラピー・カタパルトが神奈川県と覚書を交わす
ロンドン 科学研究と商業化との間の橋渡しをすることで、英国の細胞・遺伝子療法産業の成長に専心する英国の組織セル・セラピー・カタパルトは本日、神奈川県と了解覚書を交わしたことを発表します。覚書に署名したのは神奈川県の黒岩祐治知事とセル・セラピー・カタパルトのキース・トンプソン最高経営責任者（CEO）です。...
View ArticleClik here to view.
Acelity Acquires SNaP® Disposable Negative Pressure Wound Therapy System to...
SAN ANTONIO Acelity, a global wound care and regenerative medicine company, announced it has acquired the SNaP® Therapy System, a disposable negative pressure wound therapy (NPWT) line of products...
View ArticleClik here to view.
亚洲痤疮理事会和Galderma携手改善对痤疮的认识和处治
瑞士洛桑 — 亚洲痤疮理事会(AAB)和Galderma正在邀请候选人申请一笔1万美元的经费，以便为改善痤疮处治的最佳实践作出贡献。...
View ArticleClik here to view.
Study Shows Flexor® Parallel™ Rapid Release™ Ureteral Access Sheath Allows...
BLOOMINGTON, Ind. A recent study by Breda et al shows that the Flexor® Parallel™ Rapid Release™ Ureteral Access Sheath (UAS) provides physicians an option to use one wire guide for treatment and...
View ArticleClik here to view.
アジア・ニキビ対策委員会とガルデルマがニキビの理解と管理の促進で力を合わせる
スイス・ローザンヌ （ビジネスワイヤ） — 「アジア・ニキビ対策委員会」（Asian Acne Board、AAB）とガルデルマは、ニキビの管理におけるベストプラクティスを改善することに貢献する研究で、助成金1万米ドルの応募を呼びかけます。...
View ArticleClik here to view.
bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to...
CAMBRIDGE, Mass. & SEOUL, Korea bluebird bio, Inc. (Nasdaq: BLUE) and ViroMed Co., Ltd. today announced that they have entered into an exclusive license agreement to research, develop and...
View Article